Amphastar Pharmaceuticals (AMPH) Liabilities and Shareholders Equity (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Liabilities and Shareholders Equity of $1.6 billion for Q1 2026, up 1.35% year-over-year from $1.6 billion in Q1 2025, and up 1.16% quarter-over-quarter from $1.6 billion in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $1.6 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 1.35% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $6.6 billion (up 5.1% YoY), while the FY2025 annual figure was $1.6 billion, up 3.29% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $1.6 billion, up from $1.6 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $1.7 billion in Q3 2025, with the low at $716.2 million in Q1 2022.
- The 5-year median for Liabilities and Shareholders Equity is $1.5 billion (2023), against an average of $1.3 billion.
- The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity surged 112.56% in 2023, then rose 0.04% in 2024.
- Amphastar Pharmaceuticals' Liabilities and Shareholders Equity stood at $742.0 million in 2022, then soared by 103.9% to $1.5 billion in 2023, then grew by 4.27% to $1.6 billion in 2024, then gained by 3.29% to $1.6 billion in 2025, then advanced by 1.16% to $1.6 billion in 2026.
- Business Quant data shows AMPH's Liabilities and Shareholders Equity at $1.6 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Amphastar Pharmaceuticals | 945.98 Mn | 655.86 Mn | 93.47 Mn | 1.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.74 Bn |
| Mar 31, 2026 | 1.65 Bn |
| Dec 31, 2025 | 1.63 Bn |
| Sep 30, 2025 | 1.67 Bn |
| Jun 30, 2025 | 1.62 Bn |
| Mar 31, 2025 | 1.63 Bn |
| Dec 31, 2024 | 1.58 Bn |
| Sep 30, 2024 | 1.55 Bn |
| Jun 30, 2024 | 1.49 Bn |
| Mar 31, 2024 | 1.57 Bn |
| Dec 31, 2023 | 1.51 Bn |
| Sep 30, 2023 | 1.54 Bn |
| Jun 30, 2023 | 1.38 Bn |
| Mar 31, 2023 | 773.66 Mn |
| Dec 31, 2022 | 741.99 Mn |
| Sep 30, 2022 | 726.70 Mn |
| Jun 30, 2022 | 723.72 Mn |
| Mar 31, 2022 | 716.24 Mn |
| Dec 31, 2021 | 671.53 Mn |
| Sep 30, 2021 | 651.68 Mn |